New combo attack on Tough-to-Treat lung cancer
NCT ID NCT02525757
Summary
This study is testing the safety of adding a new immunotherapy drug (MPDL3280A) to the standard treatment of chemotherapy and radiation for patients with non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this three-part combination is safe and can better control the cancer. Up to 52 adults with this specific type of lung cancer will receive the treatment and be closely monitored for side effects and how well the cancer responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.